Applications of single-cell multi-omics in cancer research DOI Creative Commons
Óscar Arrieta, Rafael Rosell, Andrés F. Cardona

et al.

Medicina, Journal Year: 2023, Volume and Issue: 45(4), P. 621 - 626

Published: Dec. 31, 2023

Precision oncology, defined as molecular profiling of tumors to identify targetable alterations, is rapidly developing, and has entered the mainstream clinical practice. Genomic testing involves stakeholders workingnin a coordinated fashion deliver high-quality tissue samples laboratories, where appropriate next-generation sequencing (NGS) analysis leads actionable results. Clinicians should be familiar with types genomic variants reported by laboratory technology used determine effects, including limitations current methodologies reports. results are best interpreted multidisciplinary input reduce uncertainty in recommendations relating documented variant

Language: Английский

Harnessing Artificial Intelligence for Precision Diagnosis and Treatment of Triple Negative Breast Cancer DOI
Md Sadique Hussain, Prasanna Srinivasan Ramalingam,

Gayathri Chellasamy

et al.

Clinical Breast Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Potential targets for synergistic bipolar irreversible electroporation in tumor suppression through transcriptomics and proteomics analysis DOI
Yancheng Wang, Xinlei Liu, Rui Liu

et al.

Gene, Journal Year: 2025, Volume and Issue: 952, P. 149420 - 149420

Published: March 16, 2025

Language: Английский

Citations

0
Multi-omic profiling in breast cancer: utility for advancing diagnostics and clinical care DOI
Emna El Gazzah, Scott Parker, Mariaelena Pierobon

et al.

Expert Review of Molecular Diagnostics, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

Breast cancer remains a major global health challenge. While advances in precision oncology have contributed to improvements patient outcomes and provided deeper understanding of the biological mechanisms that drive disease, historically, research patients' allocation treatment heavily relied on single-omic approaches, analyzing individual molecular dimensions such as genomics, transcriptomics, or proteomics. these deep insights into breast biology, they often fail offer complete disease's complex landscape. In this review, authors explore recent advancements multi-omic realm using clinical data show how integration can more holistic alterations their functional consequences underlying cancer. The overall developments AI are expected complement diagnostics through potentially refining prognostic models, selection. Overcoming challenges cost, complexity, lack standardization is crucial for unlocking full potential multi-omics care enable advancement personalized treatments improve outcomes.

Language: Английский

Citations

0
Decoding the Role of CDCA Genes in Breast Cancer Progression: Insights From in Silico and Functional Assay DOI Creative Commons

Yongsheng Zhao,

Xiaocha Ma,

Jun Zhou

et al.

Asia-Pacific Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: April 17, 2025

ABSTRACT Background The cell division cycle‐associated (CDCA) genes regulate key cellular processes like cycle progression and division. This study evaluates the diagnostic clinical relevance of CDCA in breast cancer. Methodology Breast cancer normal lines were cultured analyzed for gene expression using RT‐qPCR further validated public databases. Functional assays, including proliferation, colony formation, wound healing, performed following siRNA‐mediated knockdown CDCA2 CDCA3. Mutational, CNV, methylation, survival analyses, along with miRNA regulation PPI network construction, conducted to explore role progression. Results Our findings revealed significant upregulation compared controls, all these exhibiting highest potential based on AUC values ROC analysis. Pathological stage analysis indicated that CDCA5 CDCA7 significantly varied across different stages. Mutational showed had mutation rate, missense mutations being most common. CNV amplification events several genes, particularly CDCA2, CDCA3, CDCA4, CDCA7. Promoter methylation hypomethylation cancer, which correlated negatively their expression. Survival demonstrated high CDCA5, CDCA7, CDCA8 was associated worse overall survival, highlighting prognostic significance. Furthermore, immune infiltration correlations between types, suggesting a modulation. identified specific miRNAs targeting showing as biomarkers. Lastly, CDCA3 cells reduced migration, indicating critical roles tumor growth metastasis. Conclusion highlights promising biomarkers Their correlates poor impairs growth, emphasizing therapeutic targets. These suggest could be integrated into practice improved management. Clinical trial number Not applicable.

Language: Английский

Citations

0
Unveiling the potential of Muscadine grape Skin extract as an innovative therapeutic intervention in cancer treatment DOI Creative Commons
Sarah Otun, Ikechukwu Achilonu, Valerie Odero‐Marah

et al.

Journal of Functional Foods, Journal Year: 2024, Volume and Issue: 116, P. 106146 - 106146

Published: April 6, 2024

The use of muscadine grape extracts (MGSE). in cancer treatment has gained attention due to its distinctive composition polyphenols and antioxidants. This review analyses the reported anti-cancer properties MGSE. study commences by reviewing phytochemical MGSE, highlighting presence resveratrol ellagic acid. Furthermore, underscores mechanism action these active compounds MGSE combating cells. potential compared other plant is also discussed. In addition, it highlights MGSE's superiority distinct preventing growth comparing with those medicinal plants. Lastly, combinatory approaches traditional therapies, safety, possible side effects were highlighted. work provides an understanding positioning as a valuable unique challenge within field therapy.

Language: Английский

Citations

3
Visualizing DNA/RNA, Proteins, and Small Molecule Metabolites within Live Cells DOI
Dongling Jia,

Minhui Cui,

Xianting Ding

et al.

Small, Journal Year: 2024, Volume and Issue: 20(46)

Published: Aug. 3, 2024

Live cell imaging is essential for obtaining spatial and temporal insights into dynamic molecular events within heterogeneous individual cells, in situ intracellular networks, vivo organisms. Molecular tracking live cells also a critical general requirement studying physiological processes biology, cancer, developmental neuroscience. Alongside this context, review provides comprehensive overview of recent research progress live-cell RNAs, DNAs, proteins, small-molecule metabolites, as well their applications diagnosis, immunodiagnosis, biochemical diagnosis. A series advanced techniques have been introduced summarized, including high-precision imaging, high-resolution low-abundance multidimensional multipath rapid computationally driven methods, all which offer valuable disease prevention, treatment. This article addresses the current challenges, potential solutions, future development prospects field.

Language: Английский

Citations

2
Synthesis, characterization, and applications of starch-based nano drug delivery systems for breast cancer therapy: A review DOI

Shijuan Mei,

R. Roopashree,

Farag M. A. Altalbawy

et al.

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 280, P. 136058 - 136058

Published: Sept. 26, 2024

Language: Английский

Citations

2
Adherence to HEI-2010 and odds of breast cancer according to the menopause status: Evidence from Middle Eastern Country DOI Creative Commons
Soraiya Ebrahimpour‐Koujan,

Sanaz Benisi-Kohansal,

Leila Azadbakht

et al.

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(3), P. e0300986 - e0300986

Published: March 28, 2024

Background Majority of earlier studies have assessed the association between individual healthy eating index-2010 (HEI-2010) and odds breast cancer (BC). However, no study has been conducted on effect compliance with HEI-2010 BC in Iranian population a large sample size. Therefore, we aimed to investigate relationship population. Method This population-based case-control included 350 newly diagnosed cases 700 controls randomly selected from adult women. was examined using validated questionnaires. The adherence among participants divided into four categories. general characteristics quartiles HEI score for categorical variables continuous were evaluated chi-square one-way analysis variance, respectively. Also, logistic regression analysis, dietary intakes quartiles. confounding adjusted different models. Result People highest had 60% lower (OR: 0.40; 95% CI: 0.27, 0.57) than those lowest post-menopause After controlling age energy intake, individuals 78% less likely compared 0.22; 0.14, 0.33). Adjustments other potential confounders including demographic factors made stronger 0.21; 0.13, 0.32). remained significant even after taking BMI model 0.27; 0.17, 0.43). Conclusion Finally, this found an cancer. particularly seen postmenopausal No pre-menopausal.

Language: Английский

Citations

1
Prediction of Oncotype DX Recurrence Score by Evaluating the Peritumoral Tumor Budding in Early-stage Breast Carcinoma DOI Creative Commons
Jinah Chu, JEONGEUN DO, Sung‐Im Do

et al.

Anticancer Research, Journal Year: 2023, Volume and Issue: 43(12), P. 5563 - 5572

Published: Nov. 29, 2023

The Oncotype DX Recurrence Score (ORS) predicts the likelihood of recurrence and benefit chemotherapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative early-stage breast carcinoma (ESBC). Tumor budding (TB) is a poor prognostic carcinoma. This study aimed to determine clinicopathological significance TB predicting ORS ESBC.We included 359 ER-positive, HER2-negative ESBC. number peritumoral was assessed, cases were categorized into TB-low (<10 buds) TB-high (≥10 groups.Patients ESBC (170/359; 47.4%) showed significantly higher median (15.0 vs. 13.0) than those tumors (189/359; 52.6%). Multivariate analysis revealed that high level an independent predictive for ESBC.High independently predicted ORS. may serve as surrogate marker

Language: Английский

Citations

3
Age-related Differences in Spatially Resolved Transcriptomic Profiles of Patients With Hormone Receptor-positive Breast Carcinoma DOI Creative Commons
Jinah Chu, Sung‐Im Do, Hyun Soo Kim

et al.

Anticancer Research, Journal Year: 2024, Volume and Issue: 44(6), P. 2605 - 2616

Published: May 31, 2024

Background/Aim: Patients' age may influence the response to chemotherapy and clinical course of breast carcinoma. This study aimed compare spatial transcriptomic profiles between younger (≤50 years) older (>50 patients with hormone receptor (HR)-positive Patients Methods: Seven cases carcinoma were included. We performed digital profiling bioinformatic analysis investigate transcriptomes epithelial stromal compartments. Results: In compartment three young-age (YABC) cases, we found 21 up-regulated 7 down-regulated genes. The top two most genes serpin peptidase inhibitor clade A member 1 serine protease. gene ontology enrichment revealed a significant up-regulation defining ribosomal structures functions in YABCs. set that sets early late responses estrogen, interferon-α, tumor necrosis factor-α signaling significantly enriched Conclusion: described for first time age-related differences spatially resolved transcriptional pathways HR-positive Our observations highlight critical need age-specific treatment strategies management.

Language: Английский

Citations

0